These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9301836)

  • 21. [Biological markers in lung cancer].
    Nikliński J; Furman M
    Pneumonol Alergol Pol; 1991; 59(5-6):253-9. PubMed ID: 1668877
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL; Hu XL; Yue SD; Song CX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Differences in assay sensitivity of selected tumor markers in head and neck neoplasms].
    Adamiak G; Jurkiewicz D; Polberg K; Konieczna M
    Otolaryngol Pol; 1995; 49 Suppl 20():99-101. PubMed ID: 9454232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic importance of tumor markers in lung cancer.
    Ulsperger E; Karrer K
    Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):21-31. PubMed ID: 2545371
    [No Abstract]   [Full Text] [Related]  

  • 26. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
    Wu GP; Ba J; Zhao YJ; Wang EH
    Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
    [No Abstract]   [Full Text] [Related]  

  • 28. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
    Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
    Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Carcinoembryonic antigen and hormonal polypeptides in patients with lung cancer].
    Afrikian MN; Zaĭtseva TI; Bogdasarov IuB
    Med Radiol (Mosk); 1985 Apr; 30(4):7-10. PubMed ID: 2985906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New approaches in the diagnostic procedure of malignant pleural effusions.
    Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
    Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
    Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
    Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular microheterogeneity of tumor marker substances and its significance of biological recognition].
    Kuwabara M; Iwakoshi N; Ariyoshi Y
    Nihon Rinsho; 1996 Jun; 54(6):1580-6. PubMed ID: 8691612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of multiple markers to enhance clinical utility.
    Mercer DW
    Immunol Ser; 1990; 53():39-54. PubMed ID: 2100569
    [No Abstract]   [Full Text] [Related]  

  • 37. [Tumor markers--our experience. Tumor markers in ophthalmology].
    Kaneko A
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2353-6. PubMed ID: 1929455
    [No Abstract]   [Full Text] [Related]  

  • 38. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
    Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
    Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mediastinoscopy: 300 cases reported and literature reviewed.
    Tucker JA
    Laryngoscope; 1972 Dec; 82(12):2226-48. PubMed ID: 4648370
    [No Abstract]   [Full Text] [Related]  

  • 40. [Usefulness of biochemical tumor markers (CEA, Ca 19-9, ferritin and sialic acid) in diagnosis and prognosis of colonic neoplasms].
    Krasnodebski IW
    Wiad Lek; 1998; 51(3-4):132-41. PubMed ID: 9658987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.